Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects

Summary

A multi-part study to evaluate the safety and PK of single ascending doses of IDX21549 in healthy and HCV-infected subjects. The effect of food on the PK of IDX21549 will also be evaluated. Antiviral activity will also be assessed in HCV-infected subjects.

Timeline

Start

2014-03

Primary completion

2014-06

Completion

2014-06

Outcome

Outcome not reported

Stopped: “Early termination of IDX21459 was due to integration of Merck's HCV antiviral pipeline has resulted in revisions of the clinical development plan.”

Drugs

Indications